Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from EVE Health Group Limited ( (AU:EVE) ) is now available.
EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using its products, Dyspro™ and Libbo™, for women’s and men’s health conditions. This agreement aims to improve continuity of care and patient confidence by providing accessible telehealth consultations with registered nurses, reinforcing the safe use of EVE’s therapies. The initiative is expected to address significant unmet needs in both women’s and men’s health, potentially improving patient outcomes and adherence to treatment.
More about EVE Health Group Limited
EVE Health Group Limited operates in the healthcare industry, focusing on therapeutic products for women’s and men’s health. The company’s primary products include Dyspro™ for dysmenorrhoea and Libbo™ for erectile dysfunction, with a market focus on enhancing patient care through telehealth services and support programs.
Average Trading Volume: 653,718
Technical Sentiment Signal: Sell
Current Market Cap: A$7.35M
See more insights into EVE stock on TipRanks’ Stock Analysis page.